Inhaled fexlamose for moderate to severe COPD
Part of Lungs & breathing clinical trials.
This study tests an inhaled medication called fexlamose for people with moderate to severe COPD. It aims to see if this new treatment can help improve breathing and reduce symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 40 and 80 years old.
- You have COPD that is related to smoking and your breathing tests show moderate to severe blockage.
- You have been on the same COPD medications without changes for at least 4 weeks.
- You have had 2 or fewer COPD flare-ups that needed a hospital stay in the past year.
- You do not have asthma or other major lung conditions like bronchiectasis or cystic fibrosis.
- You have not had a COPD flare-up in the last 6 weeks and have no active lung infection.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This is an early-stage study testing a new inhaled medication (HRS-9821) to see if it is safe and how the body processes it. Researchers will first test it in healthy volunteers, then in people with COPD (chronic lung disease) to understand if it might help with breathing.
This trial tests a new injection called XKH001 to see if it can reduce COPD flare-ups and improve lung function. It may help people with moderate to severe COPD who have had recent flare-ups despite using standard inhaled medicines.
This study tests an experimental drug for people with moderate to severe COPD, especially those with chronic bronchitis. It aims to see how the drug affects certain markers in your body and whether it helps with your COPD symptoms.
This trial tests a new medicine called PF-07275315 for people with moderate to severe COPD. It aims to see if it can help reduce flare-ups (sudden worsening of symptoms) when added to your usual treatment.
This study tests an inhaled medication called ensifentrine to see if it can prevent flare-ups (exacerbations) in people with COPD who have had at least one moderate or severe flare-up in the past year while on their current treatment. If you qualify, you may receive the study drug or a placebo, and your COPD symptoms and flare-ups will be closely monitored.
This study tests a new medicine called Lunsekimig for people with COPD that has frequent flare-ups and high eosinophil levels (a sign of inflammation). It aims to see if it can help control symptoms better than a placebo (a dummy treatment).
Hear when a new COPD trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.